Myth-buster
In a 120-patient trial, N-acetyl cysteine (1200 mg/day) failed to significantly reduce contrast-induced kidney injury — while a statin cut the rate from 32.5% to 12.5%.
This single RCT challenges the popular notion that NAC is a reliable protector against kidney damage from contrast dye, but with only 120 patients and a specific Egyptian clinical population, the picture is far from settled — treat this as a provocative data point, not a verdict.
The study compared three groups before coronary angiography: hydration alone, hydration plus high-dose NAC (1200 mg daily), and hydration plus high-dose atorvastatin (80 mg). The NAC group saw a 20% incidence of kidney injury — lower than the 32.5% in the control group, but not enough to reach statistical significance. The statin group, however, showed a clear and significant reduction to 12.5%, suggesting that for this specific procedure, statins may be the more promising preventive strategy.
Where this fits in the evidence
This is among the first studies we've indexed on N-Acetyl Cysteine for Reduced Contrast-Induced Acute Kidney Injury — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- n = 120
- 2026-02-17
- Clinical drug investigation
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.